HIV Cure: Gene Therapy on CCR5 Receptor Showed Positive Result; One Patient Reached Undetectable Viral Levels
By Ryan Inoyori | March 10, 2014 5:41 PM EST
Scientists are now studying the possibility of replicating a genetic mutation on human T-cells to help fight HIV infection. It replicates the known genetic factor called CCR5 delta 32 that prevents HIV to attach itself with immune cells and render it unable to replicate in the body.
Engineering Immune Cells
Sangamo Biosciences conducted an experimental gene modifying strategy to control HIV effectively without ever needing any antiretroviral drugs or ART. In a small study performed on humans, researchers reported the engineering of a rare genetic mutation that is found to only 1 per cent of the world's population which protects carriers from becoming infected by the virus.
Some patients in their study received genetic modification treatment to resist HIV. They reported that some patients showed positive results by having decreased viral load during a temporary halt of antiretroviral drug treatment with surprising patient who reached undetectable viral levels in his blood.
"Sangamo's HIV suppression is promising but very early and far from a cure. This is very early study for technology and safety validation," Michael Yee analyst at RBC Capital Markets said according to Reuters.
Replicating CCR5 Delta 32
Sangamo Biosciences used a technique which disrupts a gene factor found in immune cells called CCR5 that is being used by HIV to attach itself, infect and replicate on T-cells. Altering CCR5 receptor will help disable the virus' ability to use T-cells to infect humans.
Each participant had their immune cells harvested from the blood, then researchers applied zinc-finger nucleases to edit genomes. Zinc finger nuclease breaks the copies of CCR5 gene, then infused back to the patient. However, performing such engineering isn't perfect as they cannot get every immune cell disrupted.
"About 25 per cent of the cells have at least one of the CCR5 genes interrupted," according to the CEO of Sangamo Biosciences, Edward Lanphier.
Rejection isn't a problem with this procedure since all cells came from the patient's but modified to resist HIV compared to regular immune cells.
Study notes include:
1. One week after infusion resulted in detectable modified T-cells in patients' blood.
2. Four weeks after infusion, six out of 12 patients had their ART stopped.
3. Four among six of those patients showed HIV levels dropped.
4. One patient's viral load reached undetectable levels in the blood.
5. Best responder is someone who had naturally mutated copy of CCR5 delta.
Individuals carrying disrupted CCR5 gene in their immune cells have slower progression to AIDS compared to infected patients with the undisrupted CCR5 gene. These immune cells with disrupted CCR5 gene becomes resistant against HIV and enables them to fight back infection.
To contact the editor, e-mail:
Most Popular Slideshows
- Prince William & Kate Middleton Caught Flirting In A Countryside Dinner Date [PHOTOS]
- Kate Middleton’s Mom Accused Of Being A Social Climber, Prince George Not Seen By Relatives
- Prince William & Kate Middleton Boards London Train in Casual Disguise, Royal Couple’s Incognito Plan A Huge Hit [PHOTOS]
- Angelina Jolie & Brad Pitt’s Top Secret Wedding Tramps Jennifer Aniston’s ‘Friends’ Reunion & Pregnancy Talks [PHOTOS]
Join the Conversation
- UFO Sighting in Australia: A Mysterious 'Flying' Object With Changing Colors Observed[Watch Video]
- Volcano Eruption In Iceland: Lava Erupts More Than 50 Meters High, Prompts Aviation Alert [Video]
- Artificial Micro-Humans to Replace Animals in Lab Tests: 90 Million Animal Lives Would be Saved
- Images Of Solar Flare Captured By NASA [Watch Video]
- Volatile Volcanoes Are Waking Up
- 5.5-Inch iPhone 6 is iPhone Air on Sept 19 Release Date: 5 Things to Consider Before Buying
- Pricey iPhone 6 on Release Date Likely but with 3X Retina Resolution & Mobile Payment Service – Reports
- Nexus 6 Release Date Update: Moto X+1 Look Leaked, Nexus X or Shamu Moved to Demo Phase
- Google Nexus 8 Confirmed as HTC T1 aka Volantis/Flounder with Freshly-Leaked Specs & Features – Reports
- Europe, US Next on ISIS’ Hit List, Says Saudi King; Seized ISIS Laptop Reveals Terrifying Bio-Warfare Plans
- iPhone 6 On Release Date To Feature Qualcomm MDM9625M LTE, 1GB RAM, Mobile Payment Deal With AMEX, 1334x750 Display
- HTC One M8 for Windows Vs. Nokia Lumia Icon, The Battle Of Windows Phones